Process validation is what turns a promising semi-solid or liquid formulation into a product that can be made reliably at commercial scale. This guide explains what process validation in pharma scale-up is, the three regulatory stages it follows, why scale-up needs dedicated validation work, and how a Contract Development and Manufacturing Organisation supports it across the lifecycle.
Table of Contents
- What is process validation in pharma scale-up?
- The three stages of process validation
- Why scale-up requires dedicated validation work
- Process validation for semi-solid manufacturing
- Process validation for liquid formulation production
- How Adragos Pharma supports validation across the lifecycle
- What development leaders should plan for
- Frequently asked questions
What Is Process Validation in Pharma Scale-Up?
Process validation in pharma scale-up is the documented evidence that a manufacturing process, when operated within defined parameters, consistently produces a medicinal product meeting its predetermined quality attributes. It is the regulatory and scientific framework that connects laboratory development to reliable commercial production, and it is particularly critical for semi-solid manufacturing and liquid formulation production, where rheology, homogeneity and microbiological control behave differently at larger batch sizes.
For development leaders moving a product from pilot to commercial scale, process validation is not a single event. It is a lifecycle that begins during process development and continues throughout the commercial life of the product.
The Three Stages of Process Validation
Regulatory authorities, including the European Medicines Agency and the United States Food and Drug Administration, recognise process validation as a three-stage lifecycle.
Stage 1: Process design
The commercial manufacturing process is defined based on knowledge gained from formulation development, pilot batches and risk assessment. Critical Quality Attributes and Critical Process Parameters are identified.
Stage 2: Process performance qualification
The designed process is confirmed at commercial scale through a defined number of consecutive batches that demonstrate reproducibility under routine manufacturing conditions.
Stage 3: Continued process verification
Ongoing monitoring of the commercial process ensures it remains in a state of control throughout the product lifecycle. Each stage produces documented evidence that supports regulatory submissions and routine batch release.
Why Scale-Up Requires Dedicated Validation Work
A formulation that performs consistently in a small development vessel will not automatically behave the same way in a large production vessel. Scaling introduces variables that are absent or negligible at small scale. Key challenges include the following.
- Heat transfer rates change as vessel geometry changes, affecting emulsion stability in creams, ointments and gels.
- Mixing energy and shear distribution differ across impeller designs and tank sizes, influencing particle size, viscosity and content uniformity.
- Hold times between processing steps lengthen at commercial scale, which can affect microbiological control in aqueous liquid formulations.
- Filling and packaging interfaces introduce additional variability that must be characterised.
Process validation addresses each of these variables by defining acceptable operating ranges and confirming that the product meets specification across the full range of expected manufacturing conditions.
Process Validation for Semi-Solid Manufacturing
Semi-solid manufacturing covers creams, ointments, gels and pastes. These products are sensitive to processing history, and small changes in mixing speed, temperature ramp rate or cooling profile can shift viscosity, active distribution or in-use performance. During scale-up, validation activities for semi-solids typically address the following.
- Homogeneity of the Active Pharmaceutical Ingredient across the batch.
- Globule or particle size distribution in emulsions and suspensions.
- Rheological behaviour across replicate batches.
- Microbiological quality and preservative efficacy at commercial hold times.
- Container closure compatibility with the bulk product.
The objective is to confirm that the commercial process delivers the same in-vitro and in-use performance as the formulation qualified during process development.
Process Validation for Liquid Formulation Production
Liquid formulation production, including oral solutions, oral suspensions and topical liquids, requires validation focused on dissolution behaviour, suspension stability, fill weight accuracy and microbiological integrity. For suspensions, the resuspendability of the product after storage is a Critical Quality Attribute that must be verified across validation batches. For sterile or low-bioburden liquid products, validation also extends to the filtration step, sanitisation cycles and aseptic handling where applicable.
How Adragos Pharma Supports Validation Across the Lifecycle
Adragos Pharma supports pharmaceutical and biotech companies from early process development through commercial production. Its site in Leipzig, Germany manufactures semi-solid products, including creams, gels, ointments and healing paste, together with non-sterile liquids such as solutions, drops, suspensions and emulsions, under a European Union Good Manufacturing Practice quality system. Support across the validation lifecycle typically includes the following.
- Formulation and process development with scale-up in mind from the earliest stages.
- Risk-based identification of Critical Quality Attributes and Critical Process Parameters.
- Engineering and pilot batches to characterise the process before commercial transfer.
- Process Performance Qualification batches at commercial scale.
- Analytical method validation to support release and stability testing.
- Continued Process Verification programmes that maintain the state of control over the product lifecycle.
By integrating development and commercial manufacturing under a single quality system, the transfer between scales is shortened and the documentation chain remains consistent for regulatory submissions. To discuss a scale-up or validation project, prospective customers are encouraged to request a capability review.
What Development Leaders Should Plan For
Process validation is most efficient when it is designed into the project from the outset rather than added at the end of development. Development leaders preparing for commercial scale-up should plan for the following.
- Early definition of Critical Quality Attributes and a target product profile.
- A scientifically justified scale-up strategy that accounts for vessel geometry and mixing differences.
- Sufficient analytical capacity to support validation batch testing.
- A documented control strategy that links process parameters to product quality.
- A continued process verification plan before the first commercial batch is released.
Each of these elements reduces the risk of failed validation batches and supports a smoother path to commercial supply.
Frequently Asked Questions
What is process validation in pharmaceutical scale-up?
Process validation is the documented evidence that a manufacturing process, run within defined parameters, consistently produces a product that meets its predetermined quality attributes. In scale-up it connects laboratory development to reliable commercial production.
What are the three stages of process validation?
The three stages are process design, process performance qualification and continued process verification. Together they define the process, confirm it at commercial scale and keep it in a state of control throughout the product lifecycle.
Why does semi-solid manufacturing need special validation at scale?
Creams, ointments and gels are sensitive to heat transfer, mixing energy and cooling profiles, all of which change with vessel size. Validation confirms that homogeneity, particle size and rheology remain within specification at commercial scale.
How does Adragos Pharma support process validation?
Adragos Pharma manages validation as an integrated lifecycle activity, from risk-based identification of Critical Quality Attributes through Process Performance Qualification and Continued Process Verification, with semi-solid and non-sterile liquid manufacturing at its site in Leipzig, Germany under a European Union Good Manufacturing Practice quality system.
